Wang Hong-tao, Zhao Xiang-yu, Zhao Xiao-su, Han Ting-ting, Lv Meng, Chang Ying-jun, Huang Xiao-jun
Peking University People's Hospital & Peking University Institute of Hematology, Beijing 100044, China.
Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):679-84. doi: 10.3760/cma.j.issn.0253-2727.2013.08.008.
To investigate the association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Thirty patients with hematological malignancies who underwent allo-HSCT were classified as recurrence with cGVHD (n=4), non-recurrence with cGVHD (n=14), recurrence without cGVHD (n=5) and non-recurrence without cGVHD (n=7). The different percentage of CD4⁺CD25⁻CD69⁺ regulatory T cells in bone marrow and CD4⁺CD25⁺FoxP3⁺ regulatory T cells, Th1 cells and Th17 cells in peripheral blood were analyzed by flow cytometry.
There were no significant differences in all these T-cell subsets among different groups (P>0.05). While the ratio of CD4⁺CD25⁻CD69⁺ regulatory T cells and Th1 cells (0.211±0.177) in 9 recurrence patients was significant higher than that (0.133±0.160) in 21 non-recurrence patients (P=0.033). The ratio were also significance between recurrence without cGVHD and non-recurrence without cGVHD patients (0.167±0.073 vs 0.073±0.057, P=0.048), and between recurrence with cGVHD and non-recurrence without cGVHD patients (0.218±0.113 vs 0.073±0.057, P=0.024). Furthermore, the ratio of CD4⁺CD25⁺FoxP3⁺ regulatory T cells and Th17 cells was significant lower (1.975±2.045) in 18 cGVHD patients than that of 12 without cGVHD patients (3.198±1.132, P=0.010), and the ratio was also significant lower in non-recurrence patients with cGVHD (1.695±1.178) than that of without cGVHD (3.446±1.376, P=0.028).
Our results show that the ratio of CD4⁺CD25⁻CD69⁺ regulatory T cells and Th1 cells raise in recurrence patients, and the ratio of CD4⁺CD25⁺FoxP3⁺ regulatory T cells and Th17 decrease in cGVHD patients, which suggest that the ratio of regulatory and effector T cells had association with recurrence and cGVHD in patients with allo-HSCT.
探讨异基因造血干细胞移植（allo-HSCT）后调节性T细胞与效应性T细胞比例与复发及慢性移植物抗宿主病（cGVHD）的相关性。
30例接受allo-HSCT的血液系统恶性肿瘤患者分为cGVHD复发组（n=4）、cGVHD未复发组（n=14）、无cGVHD复发组（n=5）和无cGVHD未复发组（n=7）。采用流式细胞术分析骨髓中CD4⁺CD25⁻CD69⁺调节性T细胞以及外周血中CD4⁺CD25⁺FoxP3⁺调节性T细胞、Th1细胞和Th17细胞的不同百分比。
不同组间所有这些T细胞亚群均无显著差异（P>0.05）。然而，9例复发患者中CD4⁺CD25⁻CD69⁺调节性T细胞与Th1细胞的比例（0.211±0.177）显著高于21例未复发患者（0.133±0.160）（P=0.033）。无cGVHD复发患者与无cGVHD未复发患者之间的比例也有显著差异（0.167±0.073 vs 0.073±0.057，P=0.048），cGVHD复发患者与无cGVHD未复发患者之间的比例同样有显著差异（0.218±0.113 vs 0.073±0.057，P=0.024）。此外，18例cGVHD患者中CD4⁺CD25⁺FoxP3⁺调节性T细胞与Th17细胞的比例（1.975±2.045）显著低于12例无cGVHD患者（3.198±1.132，P=0.010），cGVHD未复发患者中该比例（1.695±1.178）也显著低于无cGVHD患者（3.446±1.376，P=0.028）。
我们的结果表明，复发患者中CD4⁺CD25⁻CD69⁺调节性T细胞与Th1细胞的比例升高，cGVHD患者中CD4⁺CD25⁺FoxP3⁺调节性T细胞与Th17细胞的比例降低，这表明调节性T细胞与效应性T细胞的比例与allo-HSCT患者的复发及cGVHD有关。
